



Response Report for Review and Comment – January 2012

Venous Thromboembolism Diagnosis and Treatment

Member Groups Requesting Changes:

Marshfield Clinic

Member Groups that Reviewed the Guideline, No Changes Requested:

CentraCare
Mayo Clinic
HealthPartners Health Plan

Member Groups that Responded but the Guideline Does Not Pertain to Practice:

None

Sponsoring Health Plans Requesting Changes:

None

Sponsoring Health Plans that Reviewed the Guideline, No Changes Requested:

None

GENERAL COMMENTS:

None

MEDICAL CONTENT:

- 1) Algorithm Box# 17, page 2: In the previous response report, we had requested that heparin be clarified e.g. UFH and add fondaparinux. The work group response was, “the work group clarified the type of heparin to be unfractionated heparin (UFH)” “However, the work group did not add fondaparinux, because they felt that this was not the type of agent that would be recommended at this juncture in the algorithm.” We noticed that the type of heparin was not clarified and fondaparinux was added. After further discussion within our organization, we agree that fondaparinux would not be appropriate at this juncture (VTE Diagnosis Algorithm). We recommend to clarify the type of heparin as unfractionated heparin (UFH) and remove fondaparinux from box #17. (Marshfield Clinic)

Thank you for the observation. The work group has reviewed and recommended changing box #17 to anticoagulation. Discussion regarding specific agents is included in the annotation.

PRIORITY AIMS AND SUGGESTED MEASURES:

None

SUPPORT FOR IMPLEMENTATION:

None